KR102067850B1 - 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법 - Google Patents

하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법 Download PDF

Info

Publication number
KR102067850B1
KR102067850B1 KR1020147035427A KR20147035427A KR102067850B1 KR 102067850 B1 KR102067850 B1 KR 102067850B1 KR 1020147035427 A KR1020147035427 A KR 1020147035427A KR 20147035427 A KR20147035427 A KR 20147035427A KR 102067850 B1 KR102067850 B1 KR 102067850B1
Authority
KR
South Korea
Prior art keywords
substituted
compound
unsubstituted
alkyl
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020147035427A
Other languages
English (en)
Korean (ko)
Other versions
KR20150020214A (ko
Inventor
데이빗 아스킨
충 한
조나단 더블유. 레인
트레비스 레마처크
사가르 샤키아
씨. 그레고리 소웰
키스 엘. 스펜서
피터 제이. 스텐젤
Original Assignee
어레이 바이오파마 인크.
제넨테크, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 어레이 바이오파마 인크., 제넨테크, 인크. filed Critical 어레이 바이오파마 인크.
Publication of KR20150020214A publication Critical patent/KR20150020214A/ko
Application granted granted Critical
Publication of KR102067850B1 publication Critical patent/KR102067850B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/32One oxygen, sulfur or nitrogen atom
    • C07D239/42One nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
KR1020147035427A 2012-05-17 2013-05-17 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법 Active KR102067850B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261648473P 2012-05-17 2012-05-17
US61/648,473 2012-05-17
US201361785122P 2013-03-14 2013-03-14
US61/785,122 2013-03-14
PCT/US2013/041666 WO2013173768A1 (en) 2012-05-17 2013-05-17 Process for making hydroxylated cyclopentylpyrimidine compounds

Publications (2)

Publication Number Publication Date
KR20150020214A KR20150020214A (ko) 2015-02-25
KR102067850B1 true KR102067850B1 (ko) 2020-01-17

Family

ID=48485537

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147035427A Active KR102067850B1 (ko) 2012-05-17 2013-05-17 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법

Country Status (20)

Country Link
US (4) US9416110B2 (https=)
EP (1) EP2861582B1 (https=)
JP (1) JP6284928B2 (https=)
KR (1) KR102067850B1 (https=)
CN (1) CN104470913B (https=)
AU (1) AU2013262505B2 (https=)
BR (1) BR112014028589B1 (https=)
CA (1) CA2873654C (https=)
DK (1) DK2861582T3 (https=)
ES (1) ES2582557T3 (https=)
IL (1) IL235715A (https=)
MX (1) MX353384B (https=)
MY (1) MY169028A (https=)
NZ (1) NZ702935A (https=)
PL (1) PL2861582T3 (https=)
RU (1) RU2643811C2 (https=)
SG (1) SG11201407616TA (https=)
SI (1) SI2861582T1 (https=)
WO (1) WO2013173768A1 (https=)
ZA (1) ZA201409261B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
HRP20200992T1 (hr) 2012-05-17 2020-10-16 Genentech, Inc. Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci
RU2014151017A (ru) 2012-05-17 2016-07-10 Аррэй Байофарма Инк. Способ получения гидроксилированных циклопентилпиримидинов
AU2013262505B2 (en) 2012-05-17 2017-09-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
ES2765511T3 (es) 2013-11-15 2020-06-09 Hoffmann La Roche Procesos para la preparación de compuestos de pirimidinilciclopentano
ES2749100T3 (es) * 2014-09-26 2020-03-19 Hoffmann La Roche Procesos para preparar compuestos de (ciclopentil[d]pirimidin-4-il)piperazina
TWI777658B (zh) 2016-08-10 2022-09-11 瑞士商赫孚孟拉羅股份公司 包含Akt蛋白質激酶抑制劑之醫藥組合物
IL295929A (en) 2020-06-16 2022-10-01 Hoffmann La Roche Process for making hydroxylated cyclopentylpyrimidine compounds
KR102689151B1 (ko) * 2021-09-06 2024-07-29 연세대학교 산학협력단 Akt 신호경로 억제제를 유효성분으로 포함하는 아토피피부염의 예방 또는 치료용 조성물

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050016A1 (en) * 2009-10-23 2011-04-28 Eli Lilly And Company Akt inhibitors

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09506369A (ja) 1993-12-12 1997-06-24 アグロジーン・リミテッド 菌類感染から植物を保護するための新規方法
AU724216B2 (en) 1997-04-07 2000-09-14 Merck & Co., Inc. A method of treating cancer
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
CA2363169A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
CN1178931C (zh) * 1999-06-03 2004-12-08 帝国脏器制药株式会社 取代吡唑化合物
WO2001022963A1 (en) 1999-09-27 2001-04-05 Merck & Co., Inc. Method of preventing osteoporosis
JP4550811B2 (ja) 2003-06-09 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パピローマウイルスのインヒビター
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
UA95641C2 (xx) * 2006-07-06 2011-08-25 Эррей Биофарма Инк. Гідроксильовані піримідильні циклопентани як інгібітори акт протеїнкінази$гидроксилированные пиримидильные циклопентаны как ингибиторы акт протеинкиназы
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2209775A1 (en) 2007-10-09 2010-07-28 UCB Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
CN102459165B (zh) 2009-04-15 2015-09-02 Abbvie公司 抗病毒化合物
EP2592933B1 (en) 2010-07-16 2017-04-05 Anderson Gaweco Mif inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
RU2014151017A (ru) 2012-05-17 2016-07-10 Аррэй Байофарма Инк. Способ получения гидроксилированных циклопентилпиримидинов
HRP20200992T1 (hr) 2012-05-17 2020-10-16 Genentech, Inc. Amorfni oblik pirimidinil-ciklopentanskog spoja koji inhibira akt, te njegovi pripravci i postupci
CN104471070B (zh) 2012-05-17 2018-09-25 基因泰克公司 制备羟基化环戊并嘧啶化合物和其盐的方法
AU2013262505B2 (en) 2012-05-17 2017-09-21 Array Biopharma Inc. Process for making hydroxylated cyclopentylpyrimidine compounds
MX350443B (es) 2012-05-17 2017-09-06 Genentech Inc Proceso para hacer compuestos de aminoácidos.
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
WO2014150395A1 (en) 2013-03-15 2014-09-25 Shifa Biomedical Corporation Anti-pcsk9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011050016A1 (en) * 2009-10-23 2011-04-28 Eli Lilly And Company Akt inhibitors

Also Published As

Publication number Publication date
IL235715A (en) 2017-02-28
MX353384B (es) 2018-01-10
CN104470913A (zh) 2015-03-25
CA2873654C (en) 2021-06-22
RU2643811C2 (ru) 2018-02-06
US20150152067A1 (en) 2015-06-04
US9790190B2 (en) 2017-10-17
RU2014151050A (ru) 2016-07-10
AU2013262505A1 (en) 2015-01-22
DK2861582T3 (en) 2016-08-22
US20180258054A1 (en) 2018-09-13
US9676730B2 (en) 2017-06-13
MX2014013862A (es) 2015-05-07
PL2861582T3 (pl) 2016-11-30
AU2013262505B2 (en) 2017-09-21
US20170247337A1 (en) 2017-08-31
EP2861582B1 (en) 2016-05-25
JP2015517532A (ja) 2015-06-22
US9416110B2 (en) 2016-08-16
MY169028A (en) 2019-02-04
ZA201409261B (en) 2017-05-31
SG11201407616TA (en) 2015-03-30
KR20150020214A (ko) 2015-02-25
US20160318877A1 (en) 2016-11-03
IL235715A0 (en) 2015-02-01
EP2861582A1 (en) 2015-04-22
ES2582557T3 (es) 2016-09-13
CN104470913B (zh) 2018-07-20
SI2861582T1 (sl) 2016-09-30
BR112014028589B1 (pt) 2022-08-23
NZ702935A (en) 2017-02-24
WO2013173768A1 (en) 2013-11-21
JP6284928B2 (ja) 2018-02-28
CA2873654A1 (en) 2013-11-21
BR112014028589A2 (pt) 2017-07-25
HK1208451A1 (en) 2016-03-04

Similar Documents

Publication Publication Date Title
KR102067850B1 (ko) 하이드록실화 사이클로펜틸피리미딘 화합물 제조 방법
JP6196294B2 (ja) アミノ酸化合物を製造するためのプロセス
JP2020059762A (ja) (シクロペンチル[d]ピリミジン−4−イル)ピペラジン化合物を調製する方法
HK1208451B (zh) 用於製造羥基化的環戊基嘧啶化合物的方法
HK40024946B (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK40024946A (en) Process for preparing an intermediate in the synthesis of (cyclopentyl[d]pyrimidin-4-yl)piperazine compounds
HK1208857B (en) Process for making amino acid compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20141217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20180517

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20190612

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20191223

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20200113

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20200113

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20221221

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20231227

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20241224

Start annual number: 6

End annual number: 6